Highbridge Capital Management LLC Increases Stock Position in Olink Holding AB (publ) (NASDAQ:OLK)

Highbridge Capital Management LLC raised its stake in shares of Olink Holding AB (publ) (NASDAQ:OLK) by 4.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 567,711 shares of the company’s stock after purchasing an additional 21,675 shares during the period. Highbridge Capital Management LLC owned 0.46% of Olink Holding AB (publ) worth $14,465,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in OLK. FIL Ltd bought a new stake in Olink Holding AB (publ) in the fourth quarter worth $204,394,000. Alpine Associates Management Inc. increased its holdings in shares of Olink Holding AB (publ) by 0.9% in the 2nd quarter. Alpine Associates Management Inc. now owns 2,604,720 shares of the company’s stock worth $66,368,000 after buying an additional 22,375 shares during the last quarter. Water Island Capital LLC purchased a new stake in shares of Olink Holding AB (publ) during the 4th quarter valued at about $41,360,000. Trium Capital LLP bought a new position in shares of Olink Holding AB (publ) in the 2nd quarter valued at about $16,734,000. Finally, Absolute Gestao de Investimentos Ltda. purchased a new position in Olink Holding AB (publ) in the first quarter worth about $12,853,000. Hedge funds and other institutional investors own 30.19% of the company’s stock.

Olink Holding AB (publ) Price Performance

Shares of OLK stock opened at $26.08 on Thursday. The company has a market cap of $3.24 billion, a PE ratio of -96.59 and a beta of 0.52. Olink Holding AB has a 1 year low of $14.10 and a 1 year high of $26.09. The stock’s 50 day simple moving average is $26.08 and its two-hundred day simple moving average is $24.72.

Olink Holding AB (publ) Profile

Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on.